Abstract Ovarian cancer is currently the most lethal gynecologic cancer in the United States.
Introduction
Ovarian cancer is the sixth most common malignancy in women and the most lethal gynecologic cancer in the United States, with approximately 22,000 new cases and 16,000 deaths occurring annually [16] . Current therapies such as surgery, chemotherapy and radiotherapy usually fail to control advanced stages of the disease. This highlights the crucial need to develop novel therapeutic strategies for the control of ovarian cancer. Alternative approaches such as immunotherapeutic strategies to enhance immune responses may serve as an important method to control ovarian tumors.
One approach for the treatment of ovarian cancer by the immune system is the employment of adjuvants such as toll-like receptor (TLR) ligands that can activate both the innate and adaptive immunity (for reviews, see [12] ). It is clear that TLR ligands play a crucial role in enhancing innate and adaptive immune responses (for reviews, see [1] [2] [3] 15] ). TLR 3 ligands, such as viral double-stranded RNA and its synthetic analog, polyriboinosinic:polyribocytidylic acid (poly(I:C)), have been shown to induce inflammatory cytokines and dendritic cell activation (for review see [22] ). Specifically, poly(I:C) acts on both TLR3 in the endosome and MDA5 in the cytosol, and both pathways in dendritic cells/macrophages can induce natural killer (NK) cell activation. Recently, intraperitoneal injection of poly(I:C) was found to inhibit lung and liver metastasis of B16 melanoma cells, leading to prolonged survival of the mice [17] . However, since TLR3 is located in the endosomal compartment, it is challenging for poly(I:C) to efficiently penetrate the cell membrane and bind to its receptor. Thus, it is important to develop strategies to enhance the transfection efficiency in order to improve the uptake of (poly(I:C)) into the effector cells in order to enhance the antitumor effects against tumors.
Polyethylenimine (PEI) has emerged as a promising approach to increase the transfection efficiency of nucleic acids such as DNA administered in vivo. PEI has been used in conjugation with several other DNA vectors and has led to a significant enhancement of transfection efficiency [18, 28] . In addition, PEI has been used to enhance the delivery of siRNA [7] . Thus, the employment of polyethylenimine (PEI) may potentially serve as an effective method to improve the transfection efficiency, thus improving the uptake of nucleic acids, such as poly(I:C) into dendritic cells in vivo.
In the current study, we plan to explore the combination of poly(I:C) with PEI to generate significant therapeutic antitumor effects against mouse ovarian surface epithelial cells (MOSEC) ovarian tumors. We observed that mice treated with poly(I:C) in combination with PEI generate significant therapeutic antitumor effects against MOSEC tumors. Furthermore, we found that NK cells play a significant role in the antitumor effects generated by treatment with poly(I:C) in combination with PEI. Intraperitoneal administration of poly(I:C) with PEI led to the uptake of poly(I:C) mainly by CD11b? macrophages, resulting in the high expression of MHC class II and IL-12 (M1 phenotype). Finally, adoptive transfer of CD11b? macrophages from mice treated with poly(I:C) and PEI was found to lead to increased proliferation and activation of NK cells from recipient mice. The clinical implications of the current study are discussed.
Materials and methods

Animals and cell lines
Female C57BL/6 mice, 5-8 weeks of age, were purchased from National Cancer Institute (Frederick, MD). All animals were maintained under specific pathogen-free conditions, and procedures were performed according to approved protocols and in accordance with recommendations for the proper use and care of laboratory animals. The MOSEC cell lines were originally derived from mouse ovarian surface epithelial cells and generated as shown previously [25] . Luciferase-expressing MOSEC cell line (MOSEC/luc) was also previously generated in 2007 as described by Hung et al. [14] . TC-1 cells were obtained by cotransformation of primary C57BL/6 mouse lung epithelial cells with HPV-16 E6 and E7 and an activated ras oncogene as previously described [20] . All cells were maintained in RPMI 1640 medium (Invitrogen, Carlsbad, CA, USA) supplemented with 2 nM glutamine, 1 mM sodium pyruvate, 20 mM HEPES, 50 lM b-mercaptoethanol, 100 IUml -1 penicillin, 100 lg ml -1 streptomycin, and 10% fetal bovine serum (FBS) (Gemini BioProducts, Woodland, CA, USA) at 37°C with 5% CO 2 .
Reagents
Polyriboinosinic:polyribocytidylic acid (poly(I:C)) was purchased from Sigma (Sigma-Aldrich Ò , USA) and diluted with PBS into 1 mg/ml stack before operating. In vivojetPEI TM , a linear polyethylenimine(PEI), was purchased from Polyplus transfection (Polyplus transfection, CA, USA) and mixed with poly(I:C) at N/P = 8 as the manufacture suggested. For the PE-labeled-poly(I:C) used in the poly(I:C) transfection experiment, poly(I:C) was labeled using the Label IT Ò Nucleic Acid Labeling Kit from Mirus (Mirus Bio., WI, USA) based on the manufacture's instructions.
In vitro tumor killing assay
Groups of C57BL/6 mice (3 per group) were i.p. injected with high-dose poly(I:C) (20 lg/mouse), low-dose poly(I:C) (1 lg/mouse), low-dose poly(I:C) in combination with PEI (0.16 ll/mouse, N/P = 8), PEI(0.16 ll/mouse), and equal amount of PBS (200 ll), killed 3 days before. The mice were euthanized by CO 2 asphyxiation, their abdomens were wiped with 70% alcohol, 8-9 ml of cold sterile PBS was injected into the peritoneal cavity, and peritoneal exudate cells (PECs) were harvested through syringe needle dripping. MOSEC/luc cells were seeded into 96-well microplate at 1 9 10 4 /well in complete medium 1 day before, and 5 9 10 5 PECs were added in triplicates at titrated effecter to target ratios. The plate was imaged for bioluminescence activity (Xenogen IVIS 200) after culturing for 16-h in incubator. For parallel experiments, some mice also received in vivo depletion of peritoneal NK cell as indicated. Those mice were i.p. injected with 200 ll NK1.1mAb (PK136, Harlan bioproducts, WI, USA) every other day, 4 days before poly(I:C) and PEI treatment.
In vivo MOSEC/luc tumor treatment b , H-2D b antibodies (BD Pharmingen, CA, USA). For intracellular staining, PECs were washed once in FACScan buffer and treated with anti-mouse CD16/CD32 (2.4G2) before stained with FITC-conjugated CD11b. Cells were subjected to intracellular cytokine staining using the Cytofix/Cytoperm kit according to the manufacturer's instructions (BD Pharmingen). Intracellular IL-12 was stained with PE-conjugated anti-mouse IL-12 (p40/p70) (BD Pharmingen, CA, USA) to identify the immune response and cytokine levels. Flow cytometry analysis was performed using FACSCalibur with CELLQuest software (BD Biosciences, MountainView, CA, USA).
In vivo antibody depletion experiments C57BL/6 mice (5 per group) were inoculated with MO-SEC/luc cells 2 9 10 5 /mouse at baseline and were treated with PBS or combined treatment (poly(I:C) ? PEI) 3 days later and repeated in a 5-day-interval. For in vivo depletion of peritoneal NK cells, mice were i.p. injected with 200 ll NK1.1mAb (PK136, Harlan bioproducts, WI, USA) every other day since one day before injecting MOSEC/luc cells to maintain a low NK cell count through the period. Depletion efficiency was checked by flow cytometry with around 90% depletion of target cells.
Poly(I:C) transfection experiment
Groups of C57BL/6 mice (2 per group) were i.p. injected with PBS, PE-labeled-poly(I:C) (1 lg/mouse) alone, or in combination with PEI (0.16 ll/mouse, N/P = 8). PECs were harvested 16 h after treatment and prepared for surface marker staining for flow cytometry analysis as previously described.
ELISA assay
To determine the level of IL-12, cytokine levels in the supernatant of 5 9 10 5 PECs harvested one day after treatment were used according to the manufacturer's instructions (eBioscience, CA, USA).
Adoptive transfer experiment
Naïve C57BL/6 mice were treated with PBS or combined treatment (poly(I:C) ? PEI) on day 0, and 200 ll NK1.1mAb (PK136, Harlan Bioproducts, WI, USA) was i.p. injected 3 times every other day, 4 days in advance. On day 1, PECs were harvested and CD11b cells were isolated using CD11b MicroBeads kit from MACS (Miltenyi Biotec.Inc., Auburn, CA, USA); 5 9 10 5 CD11b cells were then transferred adoptively i.p. into a new group of C57BL/ 6 mice. PBS and poly(I:C) ? PEI were also treated in parallel as negative and positive controls. To assess the effect of adoptively transferred CD11b cells, PECs were collected and NK cell activity and numbers were determined using flow cytometry 3 days later.
Results
Mice vaccinated with poly(I:C) in combination with polyethylenimine generate the best therapeutic antitumor effects against MOSEC tumors
In order to determine whether tumor-bearing mice treated with poly(I:C) in combination with polyethylenimine (PEI) can generate therapeutic antitumor effects, we performed in vivo tumor treatment experiments. C57BL/6 mice (5 per group) were challenged intraperitoneally with MOSEC/luc tumor cells. Four days later, mice were injected i.p. with a low-dose poly(I:C) (1 lg/mouse), a high-dose poly(I:C) (20 lg/mouse), a low-dose poly(I:C) in combination with PEI, PEI alone, or equal amount of PBS repeatedly at 5-day intervals. Tumor growth was monitored by luminescence imaging every week to monitor the therapeutic effects. As shown in Fig. 1 , mice vaccinated with poly(I:C) in combination with PEI demonstrated significantly reduced luminescence intensity over time and prolonged survival compared with mice vaccinated with poly(I:C) alone or PEI alone (P \ 0.05). We also observed that peritoneal cells isolated from mice treated with poly(I:C) in combination with PEI were capable of killing MOSEC tumor cells in vitro (see Supplementary Figure 1 ). Thus, our data indicate that mice vaccinated with poly(I:C) in combination with PEI generate the best therapeutic antitumor effects against MOSEC tumors.
Vaccination with poly(I:C) in combination with polyethylenimine generates significant numbers and activation of NK1.1? cells in vaccinated mice
We observed that MOSEC tumor cells have a significantly lower level of MHC class I expression compared with other tumor cells such as TC-1 tumors (see Supplementary Figure 2) . Since NK1.1? cells are known to be an important immune effector cells for the control of tumors with low MHC class I expression, we characterized the number of total as well as activated (CD69?) NK1.1? cells in peritoneal exudate cells (PECs) derived from mice vaccinated with poly(I:C) and PEI by flow cytometry analysis. As shown in Fig. 2a, b , we observed that mice vaccinated with poly(I:C) and PEI generated significantly higher percentage of NK1.1? cells among the PECs compared with mice vaccinated with poly(I:C) alone or PEI alone (P \ 0.05).
Furthermore, mice vaccinated with poly(I:C) and PEI generated significantly higher percentage of activated NK cells among the PECs compared with mice vaccinated with poly(I:C) alone or PEI alone (P \ 0.05) (Fig. 2c, d) . In order to eliminate the concern for contamination of poly(I:C) with LPS, we characterized the number and activation of NK cells generated in mice treated with endotoxin-free poly(I:C) and observed similar results (Supplementary Figure 2) . Thus, our data indicate that vaccination with poly(I:C) in combination with PEI generates significant numbers and activation of NK cells in vaccinated mice.
NK1.1? cells play a significant role in the antitumor effects generated by treatment with poly(I:C) in combination with PEI In order to confirm the role of NK cells in the antitumor effects caused by treatment with poly(I:C) and PEI, we carried out NK cell depletion experiments. C57BL/6 mice were inoculated with MOSEC/luc cells. Three days later, mice were treated with PBS or combined treatment (poly(-I:C) ? PEI) repeatedly with 5-day-intervals. One group of mice was depleted of NK cells using NK1.1mAb. Tumor growth was monitored by luminescence imaging. As shown in Fig. 3 , mice treated with poly(I:C) and PEI with NK cell depletion demonstrated significantly higher tumor load compared with mice treated with poly(I:C) and PEI without NK cell depletion (P \ 0.05). We also carried out in vitro tumor killing experiments using PECs from mice depleted of NK1.1? cells. We demonstrated approx 90% efficiency of depletion of NK1.1? cells, using the NK1.1mAb (see Supplementary Figure 3B ). We observed that NK1.1 depletion led to a significant reduction in MOSEC tumor cell killing by PECs isolated from mice treated with poly(I:C) and PEI compared with mice treated with PECs without NK depletion (see Supplementary Figure 3C ). Thus, our data indicate that NK cells play a significant role in the antitumor effects generated by treatment with poly(I:C) in combination with PEI. However, other factors may also potentially contribute to the observed effect. were isolated; 5 9 10 5 isolated cells were then transferred adoptively i.p. into a new group of C57BL/6 mice. Three days later, PECs from the recipient mice were collected and NK cell activity and numbers were determined using flow cytometry analysis. Figure 6b demonstrates the efficiency of isolation of the NK1.1-CD11b? cells. As shown in Fig. 6c, d , PECs isolated from recipient mice that received adoptive transfer of CD11b? cells from donor mice treated with poly(I:C) and PEI demonstrated a significantly percentage of total NK cells and CD69 ? NK cells compared with PECs isolated from recipient mice that received adoptive transfer of CD11b? cells from donor mice treated with PBS. Thus, our data indicate that adoptive transfer of CD11b? cells from mice treated with poly(I:C) and PEI leads to increased proliferation and activation of NK cells from recipient mice.
Discussion
In the current study, we observed that mice vaccinated with poly(I:C) in combination with PEI generate significant therapeutic antitumor effects against MOSEC tumor challenge. Furthermore, NK cells play a significant role in the antitumor effects generated by treatment with poly(I:C) in combination with PEI. Treatment with poly(I:C) and PEI was found to induce the M1 activation phenotype (high MHC class II and IL-12 expression) in CD11b? macrophages. Finally, adoptive transfer of CD11b? macrophages from mice treated with poly(I:C) and PEI was found to lead to increased proliferation and activation of NK cells from recipient mice.
In our study, we found that co-administration of PEI can lead to increased uptake of poly(I:C) and result in improved antitumor effects against murine ovarian tumors. This is consistent with our previous study that used an antimicrobial polypeptide LL-37 to enhance the immunostimulatory effects of the TLR9 ligand, CpG-ODN by increasing the uptake of CpG-ODN into the immune cells, thus enhancing the antitumor effects against ovarian cancer [6] . We found that treatment with the combination of CpG-ODN and LL-37 enhanced proliferation and activation of NK cells in the peritoneal cavity. Both these studies have employed a strategy to improve the uptake of the intracellular TLR ligands 3 and 9, thus leading to the activation of NK cells. The success of these two studies indicates that the strategy to enhance the uptake of ligands for intracellular TLRs could be potentially used as a general approach for enhancing the immune responses to control tumors and/or infectious diseases. IL-12 is known to be a potent NK cell activator [5, 19, 27] and is composed of p35 and p40 subunits. It has been shown that the heterodimer IL-12 p70 can induce IFN-gamma and TNF production while the p35 or the p40 subunit alone cannot [5, 19, 27] . However, the level of IL-12 p40 protein appears to correlate with the level of biologically active IL-12 [5, 19] . Thus, in Fig. 5b-d , we show IL-12 p70 intracellular staining together with IL-12 p40 ELISA to strengthen our claim. Furthermore, the effect of IL-12 on NK cells can also be observed in mice similar to that in human [5] . In addition, macrophages are also known to be a major IL- phenotype) in CD11b? macrophages in the peritoneal cavity (Fig. 5) . Macrophages are an extremely heterogeneous lineage displaying a range of both pro-and antiinflammatory phenotypes, the ''classically'' activated (or M1) macrophages, which are considered pro-inflammatory, and the other (M2) macrophages, which are considered anti-inflammatory (for reviews see [10, 11, 21] ). The M1 phenotype is characterized by high IL-12 and MHC class II and inducible nitric oxide synthase (iNOS) expression [9, 13] , whereas the M2 phenotype is characterized by elevated expression of anti-inflammatory cytokines such as IL-10. In general, M1 participate as inducer and effecter cells in polarized Th1 responses and mediate resistance against intracellular parasite and tumor. M2, on the other hand, participate in polarized Th2 reactions, promote killing and encapsulation of parasites [23] . Thus, the coadministration of poly(I:C) with PEI leads to the induction of macrophages with pro-inflammatory phenotype, resulting in potent antitumor effects against ovarian tumors.
In our study, we found that co-administration of PEI with poly(I:C) mainly led to increased uptake of poly(I:C) by CD11b? macrophages. However, we also observed a slight increase in the uptake of poly(I:C) by CD11c? dendritic cells (see Fig. 4 ). Although the current study focuses on the effect of poly(I:C) on macrophages, we cannot exclude the contribution of CD11c? cells to the antitumor effect. It has been shown that poly(I:C) can lead to an increased number of IFN-producing killer dendritic cells (IKDCs) in tumor-bearing mice [17] . Furthermore, PEI has also been shown to lead to the reprogramming of tumor-associated dendritic cells from immunosuppressive cells to efficient antigen-presenting cells via the TLR5 pathway [7] . Thus, CD11c? dendritic cells may also play a role in the observed antitumor effects generated by coadministration of poly(I:C) with PEI.
It has been shown that NK cells are particularly effective in killing tumors, which have a low MHC class I expression. In our study, we have shown that the MOSEC tumor cell line has a low MHC class I expression and is thus susceptible to NK cell-mediated killing (see Supplementary Figure 3) . Thus, our approach will be particularly effective in ovarian cancers that demonstrate low MHC class I expression levels. For clinical translation, it is important to address concerns regarding the potential toxicity associated with administration of poly(I:C) and PEI. In this regard, both poly(I:C) [24, 26] and PEI [4] have been previously used in several clinical trials and have been proven to be safe. Thus, the current strategy employing poly(I:C) and PEI has significant potential for future clinical translation in the treatment of tumors with low MHC class I expression.
Our study indicates that NK1.1? cells and macrophages play a significant role in the antitumor effects generated by treatment with poly(I:C) in combination with PEI. However, we cannot exclude the possibility of the direct effect of poly(I:C) and PEI on tumor cells. Nevertheless, our NK cell depletion experiments support the conclusion that the observed antitumor effects generated by treatment with poly(I:C) and PEI are mainly mediated by NK cells ( Fig. 3;  Supplementary Figure 4) . Furthermore, our data in Supplementary Figure 1 show that peritoneal cells, including NK cells and macrophages isolated from mice treated with poly(I:C) in combination with PEI, were capable of killing tumor cells without direct treatment on tumor cells. Thus, our data suggest that intraperitoneal administration of poly(I:C) with PEI leads to significant antitumor immunity against tumors mainly mediated by NK cells and/or macrophages.
In summary, our data indicate that PEI can potentially be used to improve the uptake of poly(I:C) by CD11b? macrophages, leading to the activation of NK cells and the control of murine ovarian tumors. Our study serves as an important foundation for future clinical translation in patients with ovarian cancer. Furthermore, this approach may potentially be used for the control of other cancers and/or infectious diseases.
